An AbbVie research and development lab in San Francisco. (Brian L. Frank for The Wall Street Journal) Drugmaker AbbVie plans to invest more than $10 billion in domestic manufacturing and other ...

AbbVie Inc. took a little shot at the Trump administration’s trade policy, as the drugmaker said Friday that rather than tariffs, tax reform is the key to boosting U.S. manufacturing. The ...

AbbVie Inc.’s (NYSE:ABBV) year is off to a very strong start. The company beat Q1 2025 revenue and EPS estimates and raised the full-year EPS guidance range by $0.10 and the full-year revenue ...

For its first quarter of this year, AbbVie's net revenue was $13.3 billion, representing a sturdy 8% improvement on a year-over-year basis. Much of this was due to a nearly 17% rise in sales of ...

Rob Stothard / Bloomberg via Getty Images AbbVie's first-quarter sales and adjusted earnings per share topped estimates. The drugmaker lifted its full-year adjusted EPS forecast by 10 cents.

AbbVie's first-quarter results improved with revenue growth powered by soaring sales for treatments in its immunology portfolio, prompting the company to raise its outlook for the year even as ...

Plus, AbbVie’s top-selling drug, Skyrizi, is made in the U.S., the CEO added. Nevertheless, AbbVie is bracing for potential near-term headwinds if pharmaceutical tariffs touch down, said CFO Reents.

AbbVie Inc. raised its profit outlook for the year on better-than-expected sales from newer autoimmune treatments, but warned its forecast doesn’t take into account any potential changes in ...

AbbVie's Q1 EPS of $2.46 beat estimates; sales rose 8.4% to $13.34 billion, topping consensus of $12.92 billion. Skyrizi and Rinvoq sales surged 70.5% and 57.2%, while Humira dropped 50.6%. Don ...

Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 8.4% year on year to $13.34 billion. Its non-GAAP profit of $2.46 per share was 2.6% ...

Gifting allows recipients to access the article for free. Tariff pressures don't seem to scare AbbVie nearly as much as the prospect of corporate tax cuts excites the North Chicago-based ...